Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202125 | 1.00 | KCNH2 (0.66) | KCNH2SLC6A2SLC6A3ADRB2ADRB3 | |
| SCHEMBL4196756 | 1.00 | KCNH2 (0.66) | KCNH2SLC6A2SLC6A3ADRB2ADRB3 | |
| SCHEMBL15451481 | 0.88 | ADRB3 (0.66) | KCNH2ADRB2ADRB3ADRB1 | |
| SCHEMBL2024941 | 0.84 | ADRB3 (0.76) | KCNH2SLC6A2SLC6A3ADRB2ADRB3 | |
| SCHEMBL2024938 | 0.84 | ADRB3 (0.76) | KCNH2SLC6A2SLC6A3ADRB2ADRB3 | |
| SCHEMBL2024942 | 0.84 | ADRB3 (0.76) | KCNH2SLC6A2SLC6A3ADRB2ADRB3 | |
| SCHEMBL5964165 | 0.84 | ADRB3 (0.54) | KCNH2SLC6A2SLC6A3ADRB2ADRB3 | |
| SCHEMBL8790970 | 0.83 | KMT2A (0.71) | KCNH2SLC6A3ADRB2ADRB1 | |
| SCHEMBL12576743 | 0.83 | KCNH2 (0.72) | KCNH2SLC6A2SLC6A3ADRB2ADRB3 | |
| SCHEMBL7014595 | 0.83 | ADRB1 (0.81) | KCNH2ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436258-A4 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | claimed |
| EP-1436258-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | Emory University (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | claimed |
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2009-01-22 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1436258-A4 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | disclosed |
| EP-1436258-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | Emory University (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | GRIN1, GRIA4, GRIA1 | KCNH2 287/4885SLC6A2 2149/4885SLC6A3 2166/4885 |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | KCNH2 382/4885SLC6A2 2030/4885SLC6A3 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.